Los Angeles Capital Management
PCVX icon

Los Angeles Capital Management’s Vaxcyte PCVX Stock Holding History

Los Angeles Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.4K Sell
1,590
-20,417
-93% -$1.11M ﹤0.01% 1353
2025
Q4 		$985K Sell
22,007
-4,896
-18% -$219K ﹤0.01% 626
2025
Q3 		$969K Sell
26,903
-12,559
-32% -$416K ﹤0.01% 711
2025
Q2 		$1.28M Buy
+39,462
New +$1.29M ﹤0.01% 583
2024
Q4 		– Sell
-8,895
Closed -$1.02M – 1213
2024
Q3 		$1.02M Buy
+8,895
New +$802K ﹤0.01% 649

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Los Angeles Capital Management's PCVX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Vaxcyte (PCVX) stake by 93% in Q1 2026, selling an estimated $1.11M and leaving 1,590 shares worth $92.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Los Angeles Capital Management first reported a position in PCVX in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.28M in Q2 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Los Angeles Capital Management held 1,590 shares of Vaxcyte worth $92.4K as of Q1 2026.
  • Los Angeles Capital Management sold 20,417 Vaxcyte shares in Q1 2026, an estimated $1.11M.
  • Vaxcyte made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1353 holding.
  • Los Angeles Capital Management first reported a position in Vaxcyte in Q3 2024 and has held it in 5 quarters since.
  • Los Angeles Capital Management's Vaxcyte position peaked at $1.28M in Q2 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.